Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000383035 | SCV000343836 | uncertain significance | not provided | 2016-07-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000694969 | SCV000823441 | uncertain significance | Nemaline myopathy 2 | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 3741 of the NEB protein (p.Gly3741Ser). This variant is present in population databases (rs375657086, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with NEB-related conditions. ClinVar contains an entry for this variant (Variation ID: 289466). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004021279 | SCV004978077 | uncertain significance | Inborn genetic diseases | 2023-11-09 | criteria provided, single submitter | clinical testing | The c.10492G>A (p.G3498S) alteration is located in exon 73 (coding exon 71) of the NEB gene. This alteration results from a G to A substitution at nucleotide position 10492, causing the glycine (G) at amino acid position 3498 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000694969 | SCV001459403 | uncertain significance | Nemaline myopathy 2 | 2020-09-16 | no assertion criteria provided | clinical testing |